- Final Results
- Total Voting Rights
- Placing to Raise US$4.2 million
- FDA Consents to Phase I Trials of HEMO-CAR-T
- Approval and Issuance of U.S. Conditioning Patent
- Submission of Complete Response to Clinical Hold
- HEMO-CAR-T Process Qualification Run Completed
- Placing to Raise £534,375
- CBR Expanded to Treatment of Cancer
- Lentivirus Re-manufacturing Completed
More ▼
Key statistics
As of last trade, Hemogenyx Pharmaceuticals PLC (HEMO:LSE) traded at 1.60, 45.45% above the 52 week low of 1.10 set on Jun 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.55 |
---|---|
High | 1.55 |
Low | 1.54 |
Bid | 1.53 |
Offer | 1.60 |
Previous close | 1.57 |
Average volume | 4.50m |
---|---|
Shares outstanding | 1.34bn |
Free float | 1.20bn |
P/E (TTM) | -- |
Market cap | 21.03m GBP |
EPS (TTM) | -0.0061 GBP |
Data delayed at least 20 minutes, as of May 03 2024 12:56 BST.
More ▼